NCT07032727 2026-04-15
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT05955261 2026-04-13
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Suspended
NCT02115295 2025-11-06
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03836209 2025-06-15
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
PrECOG, LLC.
Phase 2 Active not recruiting
NCT06696183 2025-05-29
SEQUENCE
Technische Universität Dresden
Phase 2 Recruiting
NCT06022003 2025-03-24
OGILAR
French Innovative Leukemia Organisation
Phase 2 Recruiting
NCT06667973 2025-03-12
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Not yet recruiting
NCT06221683 2024-08-22
GMCAII
Children's Hospital of Soochow University
Phase 2 Recruiting